Trade names Orathecin ATC code None Molar mass 393.349 g/mol | Routes of
administration Oral (capsules) Legal status Application withdrawn | |
 | ||
Bioavailability 25–30% (rubitecan and 9-AC; in dogs) Protein binding 97% (rubitecan), 65% (9-AC) | ||
Rubitecan (INN, marketing name Orathecin) is an oral topoisomerase inhibitor, developed by Supergen.
Contents
How to pronounce rubitecan
History
On January 27, 2004, Supergen announced that it has completed the submission of an NDA for rubitecan to the US FDA, and was accepted for filing on March 2004.
On January 2005, Supergen withdrew the NDA for rubitecan, based on feedback indicating that the current data package would not be sufficient to gain US approval, and on January 2006, the Marketing Authorization Application (MAA) filed with the European Medicines Agency (EMA) was also withdrawn.
References
Rubitecan Wikipedia(Text) CC BY-SA